Chris Freeman Biography and Net Worth

Chief Commercial Officer, Oncology of Guardant Health

Chris Freeman is the Chief Commercial Officer at Guardant Health, where he oversees the commercial strategy for Guardant’s oncology division. Prior to Guardant Health, Freeman served as Vice President at Gilead Sciences, where he led their $13B HIV treatment and prevention business and was responsible for the launch of Veklury (remdesivir) for emergency use authorization to treat COVID-19. Freeman previously worked at Elan Pharmaceuticals, where he was the commercial lead for Elan’s Alzheimer’s pipeline products, as well as at Genentech. Freeman is a member of the National Board of Directors for the Dream Foundation, a national dream-granting organization for terminally ill adults and their families. Freeman also served in the U.S. Army, and is a graduate of the United States Military Academy at West Point.

What is Chris Freeman's net worth?: The estimated net worth of Chris Freeman is at least $2.56 million as of December 5th, 2025. Mr. Freeman owns 25,987 shares of Guardant Health stock worth more than $2,564,137 as of December 17th. This net worth estimate does not reflect any other investments that Mr. Freeman may own. Additionally, Mr. Freeman receives a salary of $630,390.00 as Chief Commercial Officer, Oncology at Guardant Health. Learn More about Chris Freeman's net worth.
How old is Chris Freeman?: Mr. Freeman is currently 50 years old. There are 7 older executives and no younger executives at Guardant Health. The oldest executive at Guardant Health is Mr. Kumud Kalia, Chief Information Officer, who is 58 years old. Learn More on Chris Freeman's age.
What is Chris Freeman's salary?: As the Chief Commercial Officer, Oncology of Guardant Health, Inc., Mr. Freeman earns $630,390.00 per year. There are 2 executives that earn more than Mr. Freeman. The highest earning executive at Guardant Health is Dr. Craig Eagle M.D., Chief Medical Officer, who commands a salary of $649,130.00 per year. Learn More on Chris Freeman's salary.
How do I contact Chris Freeman?: The corporate mailing address for Mr. Freeman and other Guardant Health executives is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. Guardant Health can also be reached via phone at (855) 698-8887 and via email at [email protected]. Learn More on Chris Freeman's contact information.
Has Chris Freeman been buying or selling shares of Guardant Health?: Over the course of the past ninety days, Chris Freeman has sold $3,241,757.64 in Guardant Health stock. Most recently, Chris Freeman sold 31,452 shares of the business's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $103.07, for a transaction totalling $3,241,757.64. Following the completion of the sale, the insider now directly owns 25,987 shares of the company's stock, valued at $2,678,480.09. Learn More on Chris Freeman's trading history.
Who are Guardant Health's active insiders?: Guardant Health's insider roster includes Derek Bertocci (CFO), Ian Clark (Director), Helmy Eltoukhy (CEO), Chris Freeman (Chief Commercial Officer, Oncology), Medina Hidalgo (Director), Meghan Joyce (Director), Kumud Kalia (Insider), Samir Kaul (Director), Stanley Meresman (Director), Amelia Merrill (SVP), Terilyn Monroe (Insider), Myrtle Potter (Director), John Saia (Insider), Amirali Talasaz (COO), and Musa Tariq (Director). Learn More on Guardant Health's active insiders.
Are insiders buying or selling shares of Guardant Health?: During the last year, insiders at the sold shares 39 times. They sold a total of 975,960 shares worth more than $69,608,350.81. The most recent insider tranaction occured on December, 8th when CEO Amirali Talasaz sold 100,000 shares worth more than $10,505,000.00. Insiders at Guardant Health own 6.1% of the company. Learn More about insider trades at Guardant Health.
Information on this page was last updated on 12/8/2025.

Chris Freeman Insider Trading History at Guardant Health

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/5/2025	Sell	31,452	$103.07	$3,241,757.64	25,987

Chris Freeman Buying and Selling Activity at Guardant Health

Guardant Health Company Overview

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Today's Range

Now: $97.34

$96.95

$101.46

50 Day Range

MA: $90.23

$61.73

$111.25

2 Week Range

Now: $97.34

$29.91

$112.43

Volume

1,506,639 shs

Average Volume

2,450,053 shs

Market Capitalization

$12.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Chris Freeman Biography and Net Worth

What is Chris Freeman's net worth?

How old is Chris Freeman?

What is Chris Freeman's salary?

How do I contact Chris Freeman?

Has Chris Freeman been buying or selling shares of Guardant Health?

Who are Guardant Health's active insiders?

Are insiders buying or selling shares of Guardant Health?